Search

Your search keyword '"J. Amerena"' showing total 12 results
Start Over Author "J. Amerena" Publisher elsevier bv
12 results on '"J. Amerena"'

7. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure

Author

Milton Packer, John J.V. McMurray, Henry Krum, Wolfgang Kiowski, Barry M. Massie, Avi Caspi, Craig M. Pratt, Mark C. Petrie, David DeMets, Isaac Kobrin, Sebastien Roux, Karl Swedberg, Craig Pratt, Barry Massie, John McMurray, Eugene Connally, Mark Petrie, Susan Anderson, Jody Barnet, Robert Cody, Henry Dargie, Gary Francis, Barry Greenberg, Juerg Reichen, J. Karrasch, H. Krum, J. Horowitz, J. Amerena, A. Sindone, P. MacDonald, I. Jeffrey, I. Button, E. DeAngelis, R. Pacher, R. Davies, F. McAlister, P. Tanser, B. Sussex, G. Baumann, E. Fleck, H.-G. Olbrich, K. Werdan, H. Klein, F. Staffeld, A.M. Zeiher, C. Roediger, A. Caspi, A. Marmor, L. Reisin, Z. Vered, E. Klainman, N. Roguin, D. Tzivoni, D. David, B. Lewis, E. Abinader, M. Omary, Y. Rosenman, E. Kaluski, R.W. Breedveld, P.H. van der Burgh, P.H.J.M. Dunselman, H.J. Schaafsma, D.P. Hertzberger, N.J. Holwerda, J.A. Kragten, J. van Wijngaarden, J.L. Posma, S.A.M. Said, L.C. Slegers, R.M. Tjon Joe Gin, F.N. Wempe, J.C.L. Wesdorp, A.R. Willems, A.J.A.M. Withagen, J.M. Cornel, L.H.J. van Kempen, W. Kiowski, O. Bertel, T. Moccetti, J.J.V. McMurray, R.A. Greenbaum, P. Bennett, J. Swan, G. Davies, I. Findlay, B. Gould, S. Ball, P. Hubner, A. Lahiri, J. McLay, R. Northcote, S. Saltissi, I. Squire, J. Stephens, M. Stewart, G. Bridgen, J. Walsh, D.J. Webb, Z. Ansari, S. Baron, R. Bellinger, W. Bennet, D. Benvenuti, D. Dawley, L.C. Egbujiobi, I. Eisenstein, T. Little, A. Hertsberg, M. Greenspan, R.J. Grossman, P. Hanley, M. Jesrani, H. Kashou, R. Levites, R. Malik, B. Marmorstein, M. Schwartz, A. Nisar, R. Perelman, M.L. Schwarz, S. Sedlis, J. Srebro, M. Taveras, R. Weiss, P. Weitzman, G.K. Wetherley, M. El Shahawy, D. Kereiakes, L. Campos, G. Peterson, R.S. Small, W.R. Davis, M.-T. Olivari, W. Meengs, M. Koren, P. Slagona, S. Jennison, R. Hershberger, K.F. Browne, D.J. Farnham, S. Zelenkofske, C. Lawless, M. Nathan, T. Meyer, M. Kukin, H. Parekh, R. Berkowitz, J. Boehmer, S. Brozena, P. Dandona, G.W. Dec, V. DeQuattro, P. Fenster, M. Fowler, S. Ellaham, M. Geller, M. Gheorgiade, J. Ghali, S. Murali, S. Katz, C. Bott-Silverman, B. Singh, U. Thadani, G. Torre, J. Teerlink, T. Chandraratna, M. Kesselbrenner, A. Mukherjee, C. Che-Pin Tsai, K. Abbo, M. Goldberg, T. Smith, and R.T. Martin

Subjects
medicine.medical_specialty, business.industry, Hazard ratio, Peripheral edema, 030204 cardiovascular system & hematology, medicine.disease, Placebo, Bosentan, Confidence interval, respiratory tract diseases, Clinical trial, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Internal medicine, Heart failure, medicine, Cardiology, medicine.symptom, Cardiology and Cardiovascular Medicine, Endothelin receptor, business, medicine.drug
Abstract

Objectives The objective of this clinical trial was to evaluate the long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure. Background Endothelin may play a role in heart failure, but short-term clinical trials with endothelin receptor antagonists have reported disappointing results. Long-term trials are lacking. Methods In 2 identical double-blind trials, we randomly assigned 1,613 patients with New York Heart Association functional class IIIb to IV heart failure and an ejection fraction Results Bosentan did not influence clinical status at 9 months in either trial (p = 0.928 and p = 0.263). In addition, 321 patients in the placebo group and 312 patients in the bosentan group died or were hospitalized for heart failure (hazard ratio [HR]: 1.01; 95% confidence interval [CI]: 0.86 to 1.18; p = 0.90). The bosentan group experienced fluid retention within the first 2 to 4 weeks, as evidenced by increased peripheral edema, weight gain, decreases in hemoglobin, and an increased risk of hospitalization for heart failure, despite intensification of background diuretics. During follow-up, 173 patients died in the placebo group and 160 patients died in the bosentan group (HR: 0.94; 95% CI: 0.75 to 1.16). About 10% of the bosentan group showed meaningful increases in hepatic transaminases, but none had acute or chronic liver failure. Conclusions Bosentan did not improve the clinical course or natural history of patients with severe chronic heart failure and but caused early and important fluid retention.

Published
2017

9. ICD Implantation in Hypertrophic Cardiomyopathy: A Single Centre Experience

Author

J. Amerena and L. Segan

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Single centre, business.industry, Internal medicine, medicine, Cardiology, Hypertrophic cardiomyopathy, Cardiology and Cardiovascular Medicine, business, medicine.disease, Icd implantation
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results